Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: Toxicities and responses

Purpose: Extrapolating from our experience delivering a "boost" field of radiation concurrently with fields treating both gross and subclinical disease at the end of a course of radiation therapy, we developed a regimen to deliver concurrent chemotherapy during the last 2 weeks of a conventionally fractionated course of radiation. Patients and Methods: Patients had stage III or IV biopsy-proven squamous cell carcinoma originating from a head and neck mucosal sire. The regimen was 70 Gy delivered over 7 weeks with concurrent fluorouracil (5-FU) and cisplatin given daily with each radiation dose during the last 2 weeks. A phase I study wets performed to determine the maximum-tolerated dose (MTD) before a phase II study was conducted. Results: The MTD was 400 mg/m(2) per day for 5-FU and 10 mg/m(2) per day for cisplatin, Mucositis persisting more than 6 weeks after therapy was the dose-limiting toxicity. A total of 60 patients were Recited on the two phases of the study, Eighteen patients (35%) treated at the MTD developed prolonged mucositis, There were two cases of neutropenic sepsis, including one fatality. The actuarial 2-year rates for overall survival, freedom from relapse, and local control were 62%, 59%, and 80%, respectively. Conclusion: Preliminary locoregional control rater seem to be higher than those reported for treatment with radiation alone. Toxicity was also greater than that seen with radiation alone, but the regimen was designed to deliver an intense treatment schedule, which could be completed without significant interruptions, and to obtain high control rater above the clavicles. These end points were achieved, (C) 1999 by American Society of Clinical Oncology.